NE BUSINESS BUREAU
LUDHIANA, MAY 2
IOL Chemicals and Pharmaceuticals Ltd, a leading manufacturer of pharmaceutical APIs and speciality chemicals, on Tuesday announced that its consolidated net profit climbed to Rs 64.78 crores for the fourth quarter ended March 31, 2023.
The company has reported total income of Rs. 595.94 crores during the period ended March 31, 2023 as compared to Rs. 530.13 crores during the period ended December 31, 2022. The company’s EBITDA was Rs. 104 crore as compared to Rs. 50 crore in Q3 and Rs. 50 crore YoY.
Its total income for FY23 stood at Rs. 2,243 crore as compared to Rs. 2,216 crore in FY22. EBITDA for FY23 at Rs. 252 crore as compared to Rs. 288 crore in FY22 and net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22.
Q4FY23 Financial Highlights
| Particulars | Quarterly | Yearly | ||||||
| Q4FY23 | Q3FY23 | % QoQ | Q4FY22 | % YoY | FY23 | FY22 | % YoY | |
| Total Income | 595.9 | 530.1 | 12.4% | 579.4 | 2.9% | 2242.7 | 2,216.1 | 1.2% |
| EBITDA | 104.5 | 49.7 | 110.3% | 50.0 | 108.8% | 252.1 | 288.3 | -12.6% |
| EBITDA Margin (%) | 17.5% | 9.4% | á 810 bps | 8.6% | á 890 bps | 11.2% | 13.0% | â 180 bps |
| PAT | 65.3 | 24.2 | 169.8% | 27.7 | 135.2% | 140.0 | 165.7 | -15.5% |
| PAT Margin (%) | 11.0% | 4.6% | á 640 bps | 4.8% | á 620 bps | 6.2% | 7.5% | â 130 bps |
Commenting on the performance, Vikas Gupta, Joint Managing Director said, “The last quarter of the financial year has come out strong for us as we stabilized our operations in pharma and specialty chemicals segments with a focus on cost rationalisation and margin improvement. With significant operational, technical and commercial efficiencies, improved market combination and expecting sustainable demand as an alternative to China, we believe we are on a good upward trajectory.”
